Substantial challenges characterise the management of chronic obstructive pulmonary disease (COPD), including a progressively ...

[A]lthough our findings found that there is insufficient evidence to suggest that dupilumab use is associated with joint pain, the prevalence of joint pain observed among patients treated with ...

Summary Scientists believe that monoclonal antibody drugs, including benralizumab and dupilumab, may be breakthrough emphysema treatments.

Dupixent, which was invented using Regeneron’s proprietary VelocImmune® technology, is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 ...

The FDA approved dupilumab today as the first biologic treatment for patients with uncontrolled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype to significantly help ...

A randomized placebo-controlled study found the monoclonal antibody dupilumab (Dupixent) led to histologic remission in significantly more affected children than placebo.

Dupilumab is a human monoclonal antibody that blocks interleukin-4 and interleukin-13 pathways and has shown efficacy in five different atopic diseases marked by type 2 inflammation, including eosi ...

Dupilumab is a human monoclonal antibody that blocks the receptor shared by interleukin-4 (IL-4) and IL-13, both of which are key to the development of type 2 inflammation in chronic obstructive ...

Chronic obstructive pulmonary disease patients with type 2 inflammation saw rapid and sustained improvements after treatment with the monoclonal antibody dupilumab. The disease improvements — as ...

This monoclonal antibody is the first biologic shown to improve clinical outcomes in COPD. The data supporting the use of dupilumab in COPD will be reviewed by the United States Food and Drug ...